Replies to post #1760 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

$75 million upfront for '573

What would I be happy with for '534?

Something very similar to this, considering the possibly value for '534 in other indications other than CML:

On November 27, 2009, Incyte entered into a partnership with Novartis to form a worldwide development plan for INCB18424. For an initial payment of $210M, Novartis gained the ex-US rights to the compound. Incyte retained all rights to the compound in the US. Each company will pay for studies in their own territories. If successful, Incyte will also receive up to $1,100M in developmental in commercialization milestone payments along with tiered double digit royalties.

Having said that, I have HIGH doubts Berger could negotiate such a deal considering all his past deals (which, quite frankly, have been pathetic: Medinol, ICON (stents)--produced ZERO so far, I don't even know if ARIA ever got a penny in upfront payments from them; their other licenses to the immunotherapy company doing the prostate vaccine: produce nada upfront and nada to date); Merck deal: which was supposed to be self-funded yet cost ARIA shareholders 50 million in dilution..........which had to be renegotiated later. Maybe Berger has learned from past failings...

I'd be surprised to see a deal on Monday. Very surprised. Think the news has nothing to do with a partner and everything to do with trial design and protocol. LOL - Imagine if they said they were on "hold" for '534 due to an adverse event...LOL